Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21,004 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.
Schmidt C, Smith C, Barin B, Bakhtyari A, Bart PA, Bekker LG, Chomba E, Clumeck N, Ho D, Hoosen A, Jaoko W, Kaleebu P, Karita E, Keefer MC, van Lunzen J, McMichael A, Mehendale S, Peters B, Ramanathan VD, Robinson A, Rockstroh J, Vardas E, Vets E, Weber J, Graham BS, Than S, Excler JL, Kochhar S, Ho M, Heald A, Fast PE. Schmidt C, et al. Among authors: smith c. Hum Vaccin Immunother. 2012 May;8(5):630-8. doi: 10.4161/hv.19454. Epub 2012 May 1. Hum Vaccin Immunother. 2012. PMID: 22634443 Clinical Trial.
Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa.
Schmidt C, Jaoko W, Omosa-Manyonyi G, Kaleebu P, Mpendo J, Nanvubya A, Karita E, Bayingana R, Bekker LG, Chomba E, Kilembe W, Nchabeleng M, Nyombayire J, Stevens G, Chetty P, Lehrman J, Cox J, Allen S, Dally L, Smith C, Fast PE. Schmidt C, et al. Among authors: smith c. Hum Vaccin Immunother. 2014;10(3):714-23. doi: 10.4161/hv.27559. Epub 2013 Dec 27. Hum Vaccin Immunother. 2014. PMID: 24374365 Free PMC article.
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, Adams EM, Graham BS, Koup RA, Bailer RT, Smith C, Dally L, Farah B, Anzala O, Muvunyi CM, Bizimana J, Tarragona-Fiol T, Bergin PJ, Hayes P, Ho M, Loughran K, Komaroff W, Stevens G, Thomson H, Boaz MJ, Cox JH, Schmidt C, Gilmour J, Nabel GJ, Fast P, Bwayo J. Jaoko W, et al. Among authors: smith c. PLoS One. 2010 Sep 21;5(9):e12873. doi: 10.1371/journal.pone.0012873. PLoS One. 2010. PMID: 20877623 Free PMC article. Clinical Trial.
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, Nanvubya A, Bashir F, Bhatt K, Ogutu H, Wakasiaka S, Matu L, Waruingi W, Odada J, Oyaro M, Indangasi J, Ndinya-Achola J, Konde C, Mugisha E, Fast P, Schmidt C, Gilmour J, Tarragona T, Smith C, Barin B, Dally L, Johnson B, Muluubya A, Nielsen L, Hayes P, Boaz M, Hughes P, Hanke T, McMichael A, Bwayo J, Kaleebu P. Jaoko W, et al. Among authors: smith c. Vaccine. 2008 May 23;26(22):2788-95. doi: 10.1016/j.vaccine.2008.02.071. Epub 2008 Mar 31. Vaccine. 2008. PMID: 18440674 Clinical Trial.
Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.
Vasan S, Schlesinger SJ, Huang Y, Hurley A, Lombardo A, Chen Z, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, Sayeed E, Clark L, Dugin D, Schmidt C, Song Y, Seamons L, Dally L, Ho M, Smith C, Markowitz M, Cox J, Gill DK, Gilmour J, Keefer MC, Fast P, Ho DD. Vasan S, et al. Among authors: smith c. PLoS One. 2010 Jan 25;5(1):e8617. doi: 10.1371/journal.pone.0008617. PLoS One. 2010. PMID: 20111582 Free PMC article. Clinical Trial.
Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.
Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, Sayeed E, Clark L, Dugin D, Boente-Carrera M, Schmidt C, Fang Q, LeiBa, Huang Y, Zaharatos GJ, Gardiner DF, Caskey M, Seamons L, Ho M, Dally L, Smith C, Cox J, Gill D, Gilmour J, Keefer MC, Fast P, Ho DD. Vasan S, et al. Among authors: smith c. PLoS One. 2010 Jan 25;5(1):e8816. doi: 10.1371/journal.pone.0008816. PLoS One. 2010. PMID: 20111599 Free PMC article. Clinical Trial.
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.
Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, Boente-Carrera M, Vittorino R, Caskey M, Andersen J, Huang Y, Cox JH, Tarragona-Fiol T, Gill DK, Cheeseman H, Clark L, Dally L, Smith C, Schmidt C, Park HH, Kopycinski JT, Gilmour J, Fast P, Bernard R, Ho DD. Vasan S, et al. Among authors: smith c. PLoS One. 2011;6(5):e19252. doi: 10.1371/journal.pone.0019252. Epub 2011 May 16. PLoS One. 2011. PMID: 21603651 Free PMC article. Clinical Trial.
Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.
Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C, Smith C, Brooks M, Roberts JE, Darwin SC, Fast PE, Conlon C, Rowland-Jones S, McMichael AJ, Hanke T. Cebere I, et al. Among authors: smith c. Vaccine. 2006 Jan 23;24(4):417-25. doi: 10.1016/j.vaccine.2005.08.041. Epub 2005 Aug 24. Vaccine. 2006. PMID: 16176847 Clinical Trial.
Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.
Guimarães-Walker A, Mackie N, McCormack S, Hanke T, Schmidt C, Gilmour J, Barin B, McMichael A, Weber J, Legg K, Babiker A, Hayes P, Gotch F, Smith C, Dally L, Dorrell L, Cebere I, Kay R, Winstone N, Moore S, Goonetilleke N, Fast P; IAVI-006 Study Group. Guimarães-Walker A, et al. Among authors: smith c. Vaccine. 2008 Dec 2;26(51):6671-7. doi: 10.1016/j.vaccine.2008.09.016. Vaccine. 2008. PMID: 18812202 Clinical Trial.
Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.
Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, Ottinger J, Ferarri G, Montefiori DC, Stablein D, Smith C, Ginsberg R, Eldridge J, Duerr A, Fast P, Haynes BF; AIDS Vaccine Evaluation Group. Graham BS, et al. Among authors: smith c. PLoS One. 2010 Aug 10;5(8):e11995. doi: 10.1371/journal.pone.0011995. PLoS One. 2010. PMID: 20706632 Free PMC article. Clinical Trial.
21,004 results
You have reached the last available page of results. Please see the User Guide for more information.